CS
RPTX

Candriam SCA’s Repare Therapeutics RPTX Stock Holding History

Candriam SCA’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50,001
Closed -$529K – 685
2023
Q2 		$529K Buy
+50,001
New +$515K ﹤0.01% 675

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Candriam SCA's RPTX Position: Q3 2023 in Review

Candriam SCA sold out of Repare Therapeutics (RPTX) in Q3 2023, closing a stake of 50,001 shares — an estimated $529K sold.

Candriam SCA first reported a position in RPTX in Q2 2023 and held it in 1 quarter. The position peaked at $529K in Q2 2023. 76 funds tracked by Wall St. Rank hold RPTX as of Q3 2023.

  • Candriam SCA reported no remaining Repare Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Candriam SCA sold 50,001 Repare Therapeutics shares in Q3 2023, an estimated $529K.
  • Candriam SCA first reported a position in Repare Therapeutics in Q2 2023 and held it in 1 quarter.
  • Candriam SCA's Repare Therapeutics position peaked at $529K in Q2 2023.
  • 76 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2023.

Based on Candriam SCA's 13F filing for Q3 2023, filed 13 Nov 2023.